A limitation of our work in extending to HTT-lowering agents in clinical trials in HD patients is that our mouse lacks HTT expression both during development and through adulthood, as the Cre driver we have used is active as early as E10.5 (Weisend et al, 2009). The gene discussed is HTT; the disease is Huntington disease.